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Abstract: Noncoding RNAs (ncRNAs) defy the central dogma by representing a family of RNA
molecules that are not translated into protein but can convey information encoded in their DNA.
Elucidating the exact function of ncRNA has been a focus of discovery in the last decade and remains
challenging. Nevertheless, the importance of understanding ncRNA is apparent since these molecules
regulate gene expression at the transcriptional and post-transcriptional level exerting pleiotropic effects
critical in development, oncogenesis, and immunity. NcRNAs have been referred to as “the dark
matter of the nucleus”, and unraveling their role in physiologic and pathologic processes will provide
vast opportunities for basic and translational research with the potential for significant therapeutic
progress. Consequently, strong efforts are underway to exploit the therapeutic utility of ncRNA, some
of which have been approved by the US Food and Drug Administration and the European Medicines
Agency. The use of ncRNA therapeutics (or “vaccines” if defined as anti-disease agents) may result in
improved curative strategies when used alone or in combination with existing treatments. This review
will focus on the role of ncRNA therapeutics in prostatic carcinoma while exploring basic biological
aspects of these molecules that represent about 97% of the transcriptome in humans.
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Noncoding RNAs (ncRNAs) represent a family of RNA molecules that are not translated into protein but execute a multitude of biological functions informing significant
therapeutic potential. It is possible that some ncRNAs are nonfunctional products of spurious transcription, sometimes referred to as “junk RNA”. However, the exact number and
function of ncRNAs are still a matter of debate and the focus of active research. It has been
estimated that ncRNAs represent approximately 97% of the transcriptome, widely surpassing the amount of coding messenger RNAs (mRNAs). Approximately 30,000 molecules of
ncRNAs have been identified, which may be functionally as important as proteins. Interestingly, it has been recognized that approximately 22% of ncRNAs have been misclassified
and do encode small polypeptides, which may muddle translational research [1,2]. Overall,
ncRNAs can be divided according to their length and function. Molecules longer than
200 nucleotides are referred to as long-intervening ncRNAs (lncRNAs or lincRNAs). They
can be intronic or intergenic (lincRNAs) and play multifunctional roles regulating gene
expression. Similar to mRNAs, lncRNAs are transcribed by RNA polymerase II, have a
capped 50 end, a polyadenylated 30 end, and are processed by splicing. The nucleotide
sequence of lncRNAs is not well conserved among species. However, their function is
evolutionarily conserved, because lncRNAs with diverse sequences share a similar tertiary
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structure (hairpin) and bind to analogous proteins in different organisms [3]. In addition
to proteins, lncRNAs can also directly bind to nucleic acids with bidirectionally (sense or
antisense) base paring ability.
In contrast, the smaller ncRNA transcripts are usually about 20 nucleotides in length
and represent about 2000 to 5000 molecules with evolutionarily well-conserved sequences
that are processed by endonucleases. In common with lncRNAs, the location of smaller
ncRNAs can be intergenic or intronic.
Functionally, ncRNAs are divided into homeostatic/housekeeping and regulatory
types, although some molecules defy categorization. For example, circular RNAs (covalently closed molecules), which are usually lncRNAs that can, on occasion, encode proteins
and be structurally shorter than 200 nucleotides long [4].
Well-known homeostatic ncRNAs include transfer RNAs (tRNAs) and ribosomal
RNAs (rRNAs). tRNAs are short (~80 nucleotides) ncRNAs that ferry individual amino
acids to ribosomes allowing protein translation. In contrast, rRNAs represent a specialized
type of long ncRNAs (1500 to 3000 nucleotides in length) that constitute ~60% of the mass
of the ribosomes and bind to riboproteins, contributing to the formation of the catalytic
sites necessary for protein translation from mRNAs.
Regulatory ncRNAs have been functionally grouped into at least four main categories,
sometimes displaying overlapping features: (1) splicing RNAs, (2) self-modifying RNAs,
(3) transcriptional regulatory/gene silencing RNAs (all three usually belonging to the small
ncRNA subclass), and (4) multifunctional gene-regulatory long RNAs, exemplified by
lncRNAs. Splicing RNAs comprise small nuclear RNAs (snRNAs) that bind proteins in
the spliceosome. Self-modifying RNAs represent small nucleolar RNAs (snoRNAs), which
form part of the ribonuclear protein complex of the nucleolus and have functional similarity
to guiding RNAs, serving to chemically modify other RNA molecules. The transcriptional
regulatory/gene-silencing RNAs denote at least three types of molecules—namely, (a) small
interfering RNAs (siRNAs), involved in gene silencing; (b) microRNAs (miRNAs), which
represses mRNA translation by binding to the 30 untranslated regions of mRNA, promoting its degradation; (c) PIWI-interacting RNAs (piRNAs), which interact with the
piwi-subfamily of Argonaute proteins (a highly conserved family of RNA-binding proteins abbreviated as PIWI for the “P-element induced wimpy testis in Drosophila”), which
predominantly silence transposable elements through both epigenetic, transcriptional and
post-transcriptional mechanisms.
This overwhelming variety of ncRNA species, together with their abundance and rich
overlapping functionality, suggests regulatory effects on almost every gene. For example, it
has been estimated that in humans, one molecule of miRNA is able to bind with perfect
or imperfect complementary base pairing to hundreds (100 to 500) of different mRNA
molecules. Therefore, because more than 2000 mature miRNAs have been deposited in
the miRNABase V22 [5], this implies that potentially every one of the ~20,000 genes in the
human genome could be under miRNA regulation. Consequently, a tremendous effort to
unravel the precise involvement of ncRNAs in biology is underway, to understand their
crucial roles regulating development, immunity, and oncogenesis, and to explore novel
therapeutic applications [6].
In this regard, ncRNA agents could act as immunomodulators or even therapeutic
“vaccines”, when defined as medicines that contribute to eliminating or controlling disease,
recognizing that so far the immunogenic potential of ncRNAs has not been exploited.
Therefore, ncRNA therapeutics cannot be currently considered bona fide vaccines, and
quotation marks will be used for clarification in the following sections. ncRNA “vaccines”
can be mechanistically diverse, acting directly at a genetic or epigenetic level, or indirectly
by modulating innate and adaptive immune responses to find and destroy harmful infectious agents and cancer cells. Modulating ncRNA represents an attractive strategy in
oncologic therapy, as well as many other disciplines, and although RNA-based therapeutics
have experienced significant prominence in the last 20 years, employing predominantly
antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), important hurdles
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need to be overcome. Several products have gained regulatory approval by the US Food
and Drug Administration (FDA) or the European Medicines Agencies (EMA). However,
trial results have been disappointing so far due to a combination of factors that include
limited efficacy or significant toxicity. Alternative RNA products, such as lncRNAs and
anti-miRNAs, are currently undergoing clinical evaluation, but importantly, other ncRNA
species have not been extensively targeted to develop therapeutics yet.
In this review, we explore the potential for ncRNAs as therapeutics/“vaccines” in
prostatic carcinoma (PC), since this disease remains a significant public health burden.
Prostate cancer is the most frequently diagnosed nonskin cancer in the United States,
representing approximately 6% of all cancer deaths (disproportionately affecting black
men) and the second-most-common malignancy worldwide [7,8]. Even though the overall
survival for PC is well above 90% [8], progression to incurable castration-resistant disease
is relatively common and has been estimated to occur in 10 to 20% of cases during the first
5 years of follow-up [9]. Unfortunately, after castration resistance develops, the median
specific survival time is ~1 year after the onset of metastasis [10]. Multiple therapeutic
modalities are available for advanced PC, which have been comprehensively reviewed
recently [11,12] and include hormone therapy, chemotherapy, immunotherapy, radiation
and salvage prostatectomy, or various combinations of the aforementioned strategies. Despite significant therapeutic progress, metastatic PC remains incurable, and therefore, new
treatments, including ncRNA therapeutics (which may be used alone or in combination
with current options) are necessary. Furthermore, ncRNA may represent a multifunctional
tool, acting directly by inhibiting tumor growth and indirectly by boosting anti-tumoral
immune responses. Several lines of evidence indicate that ncRNAs modulate the immune
response [13]. In fact, unintended immunogenicity elicited by ncRNAs represents a barrier
to the applicability of these “vaccines” [14]. Our innate anti-viral defenses detect and
target RNAs via pathogen-associated molecular pattern (PAMP) recognition molecules,
such as Toll-like receptors (TLRs) and the retinoic acid-inducible gene 1 (RIG-1) receptors.
Endosomal TLR3 and cytosolic RIG-1 sense double-stranded RNAs, while endosomal
TLR7/8 sense single-stranded RNAs [15,16]. The sensing of foreign RNA leads to immune
stimulation (cytokine release) inducing toxicity and possible shock. Chemical modification of RNA has been utilized to ameliorate this unwanted immunogenicity and could be
tailored to preserve selective activation of signaling pathways that enhance anti-tumoral
effects. Interestingly, it has recently been demonstrated that at least five miRNAs are associated with PC recurrence and metastasis [17], including miR-139, which induces interferonbeta expression in prostatic adenocarcinoma cell lines by transcriptionally activating genes
downstream of RIG-1 (responsible for viral-induced interferon type-1 responses) [18]. These
results suggest that miR-139 acts as an immune agonist eliciting anti-tumoral responses and
can be modulated by ncRNA “vaccines” to treat PC. Similarly, the lncRNA HOX transcript
antisense RNA (HOTAIR) has been shown to promote invasion and metastasis in PC [19]
through inhibition of hepaCAM transcription, leading to activation of the MAPK pathway
and highlighting new therapeutic opportunities. Unfortunately, despite the encouraging
theoretical framework, none of the ncRNA therapeutics for PC has proven to be successful
in the clinic so far. In the following sections, an examination of ncRNA therapeutics approved by regulatory agencies to treat PC will be undertaken, focusing on salient aspects
that may illuminate future success.
2. Noncoding RNA Therapeutics Approved by Regulatory Agencies
Several excellent reviews have recently covered a variety of strategies to manipulate
the medicinal potential of ncRNAs by using small interfering RNAs (siRNAs), antisense
oligonucleotides (ASOs), short hairpin RNAs (shRNAs), anti-microRNAs (anti-miRNAs),
miRNA mimics, miRNA sponges, therapeutic circular RNAs (cirRNAs), and CRISPR-Cas9based gene editing [6,20,21]. The value of developing therapeutic targeting of ncRNA,
while obvious, faces significant obstacles associated with specificity, delivery, and tolerability. Some clinical trials have been stopped, mainly due to lack of efficacy, and it remains
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uncertain if proper delivery was achieved. In addition, intolerable side effects related to
activation of the immune system have promoted the termination of clinical trials. Toxicity
is commonly related to the recognition of RNA as a foreign antigen by TLRs, which activate
the transcription factor NFkB, leading to cytokine storm [22,23]. Nevertheless, this intrinsic
ability of foreign ncRNA to elicit immune responses could be harnessed to avert tumoral
immune escape and increase tolerability of ncRNA “vaccines”. Promising advances in this
direction have been achieved with other RNA therapeutics, based on breakthroughs in
immunology research [24,25]. Therefore, ncRNA could be deployed as a double-edged
sword to modulate immune activation, allowing only desirable immunotherapeutic effects while simultaneously synergizing conventional anti-oncogenic chemotherapy. For
instance, in the last decade, several studies have shown that intercellular communication
can be mediated by nanosized extracellular vesicles (exosomes), which are present in all
human body fluids and are composed of bilayer lipid membranes containing diverse cargo
molecules (proteins, lipids, ncRNAs, and DNAs) [26]. The release of exosomal content into
the cytoplasm of recipient cells after cell membrane fusion has been shown to alter protein
expression in the recipient cells, regulating adaptive immune responses to microbes and
tumors [27,28]. In addition, it has been specifically shown that ncRNA cargo in the exomes
may alter the tumor microenvironment and macrophage function [29]. Recent studies have
also addressed the role of exosomal ncRNAs in PC cell lines. Exosomal delivery of miR-26a
inhibited metastasis and tumor growth in a PC mouse xenograft model [30]. Another
report found that exosomal long lncRNA HOXD-AS1 was upregulated in the serum of
patients with metastatic PC, suggesting that it may promote tumorigenesis by acting on the
miR-361-5P/FOXM1 axis [31]. Collectively, these data reaffirm the possibility of developing
tailored ncRNA therapeutics with reduced toxicity and improved specificity by exploiting
recent innovations in chemical engineering.
Despite the rapidly evolving refinements in precision medicine, ncRNA “vaccine”
development remains daunting. Many different ncRNA therapeutic products are in the
pipeline, but only a few have been approved by the FDA and/or the EMA. Most of
them were designed to treat monogenic inherited diseases by using siRNAs or ASOs that
would specifically downregulate wild-type genes or alter pathological splicing of mutated
genes restoring functionality. However, none of these tools have been approved to treat
carcinomas due, in part, to the complex multigenic nature of malignancy. Nevertheless,
several ncRNA therapeutics are in phase II or III clinical development, which include
different molecules such as miRNA mimics and anti-miRNAs [6]. Of these, at least a few
are intended for carcinomas such as pancreatic, nonsmall-cell lung, and colorectal.
Notably, three products have been deployed in clinical trials for advanced PC (Table 1).
Apatorsen (OGX-427), attempted to target castration-resistant PC in a phase II trial
(NCT01120470). Apatorsen is a second-generation ASO that targets the cytoprotective
Hsp27, a chaperone in the heat shock family of proteins. Downregulation of Hsp27 by
apatorsen is expected to enhance the sensitivity of prostatic tumors to cytotoxic agents [32].
In the NCT01120470 randomized study, adding apatorsen to low-dose prednisone did
not change the progression-free survival when compared with prednisone alone in 74 patients with metastatic PC or pelvic recurrence who were chemotherapy naïve. However,
a significant decrease in prostate specific antigen (PSA) was observed in the apatorsen
plus prednisone arm [33]. Since this study used an endpoint (nonprogression at 12 weeks)
not currently endorsed by the Prostate Cancer Working Group criteria [34], further research on apatorsen is necessary for optimal standardization [35]. However, these results
demonstrated the potential therapeutic benefit of targeting Hsp27 with an ASO in PC and
spearheaded further research to develop alternative strategies to treat advanced disease.
Reassuringly, similar conclusions were reached in another clinical trial (NCT01454089)
analyzing the treatment of advanced urothelial carcinoma using apatorsen in combination
with docetaxel. In this phase II trial, patients randomized to apatorsen and docetaxel
had improved overall survival, compared with docetaxel alone, in metastatic or relapsed
urothelial carcinoma [36]. Conversely, the NCT01829113 double-blinded, randomized
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clinical trial for untreated metastatic nonsquamous/nonsmall-cell lung carcinoma found
no benefit from the addition of apatorsen to carboplatin and pemetrexed in 155 patients,
attesting to the histological specificity of Hsp27 inhibition for at least prostatic and urothelial carcinomas. Notably, these three clinical trials using apatorsen also established the
acceptable tolerability of this ncRNA agent [37]. Finally, the trial NCT02423590 was approved to determine the effect of apatorsen in combination with first-line chemotherapy
(gemcitabine/carboplatin) in advanced squamous cell lung carcinoma, and the results are
still unavailable to the public.
Table 1. Clinical trials for advanced prostatic carcinoma using ncRNA therapeutics.
Trial Title

Therapeutic (Type) and
MOA

Characteristics

Regimen

Major Outcomes

A Randomized Phase II
Study of OGX-427
(a Second-Generation
Antisense Oligonucleotide
to Heat Shock Protein-27)
in Patients with
Castration-Resistant
Prostate Cancer Who
Have Not Previously
Received Chemotherapy
for Metastatic Disease.
(NCT01120470)

Apatorsen/OGX-427
(a second-generation ASO)
targets cytoprotective
Hsp27. Downregulation of
Hsp27 is expected to
enhance sensitivity to
cytotoxic agents.

74 patients were
randomized to receive
apatorsen + prednisone
(n = 36) or prednisone
alone (n = 38). The
primary endpoint was
disease progression at
12 weeks.

Three loading doses at
600 mg IV within the first
10 days of initiating
treatment, followed by
weekly doses of
1000 mg IV
up to 12 weeks.

Apatorsen + prednisone
produced a significant
PSA decline but did not
change the proportion of
CRPC patients without
disease progression at
12 weeks, compared with
prednisone alone.

635 patients were
randomized. Co-primary
objectives were to evaluate
overall survival (OS) in
patients receiving
Cbz/P/C (n = 317) versus
Cbz/P (n = 318) alone.

21-day cycles of
25 mg/m2 IV Cbz on day
1 with 10 mg oral P daily
with or without 640 mg IV
of C on days 1, 8, and 15
(plus 3 prior loading
doses) until disease
progression, unacceptable
toxicity, or 10 cycles
obtained.

No significant survival
benefits were
demonstrated.

115 Chemotherapy naive
patients were randomized
to receive
docetaxel + oblimersen
(n = 58) or docetaxel
(n = 57) alone. Biologic
anti-tumor activity (based
on PSA response: Bubley
Criteria)

Docetaxel 75 mg/m2 on
day 1 or oblimersen
7 mg/kg/day continuous
IV infusion on days 1–7
with docetaxel 75 mg/m2
on day 5 every 3 weeks
for ≤12 cycles. Patients in
the docetaxel group
received a median of eight
cycles and those in the
docetaxel + oblimersen
group received a median
of six cycles

The selected endpoint
(reduction of PSA > 30%)
was not achieved in any
arm of the study,
indicating that oblimersen
was not beneficial in this
selected cohort, but Bcl-2
expression was not
analyzed.

A Randomized Phase III
Study Comparing
Cabazitaxel/Prednisone in
Combination with
Custirsen (OGX-011) to
Cabazitaxel/Prednisone
for Second-Line
Chemotherapy in Men
with Metastatic
Castrate-Resistant Prostate
Cancer (AFFINITY)
(NCT01578655)

Randomized Phase II Trial
of Docetaxel (Taxotere)
and Oblimersen
(Antisense Oligonucleotide
Directed to BCL-2) versus
Taxotere Alone in Patients
with Hormone-Refractory
Prostate
Cancer (NCT00085228)

Custirsen (ASO)
downregulates Clusterin.
Clusterin (a cytoprotective
heat shock protein)
regulates apoptosis and is
upregulated by
chemotherapy.

Oblimersen (ASO)
selectively downregulates
Bcl-2 (anti-apoptotic
proto-oncogene)
expression.

MOA = mechanism of action, Cbz = cabazitaxel, P = prednisone, C = custirsen.

Other genes have also been targeted by ncRNA therapeutics in clinical trials for advanced PC. The AFFINITY phase III trial employed the ASO custirsen (OGX-011, and
CC-8490) to downregulate Clusterin, a heat shock protein that regulates apoptosis. Interestingly, the results contradicted previous clinical trials since no significant survival benefits
could be demonstrated in patients with metastatic castration-resistant PC [38]. The trial
design included 635 men with similar demographics randomized into two arms with the
treatment arm receiving chemotherapy (cabazitaxel and prednisone) and custirsen, while
the control arm received only chemotherapy. This ASO was well-tolerated and severe adverse effects (seen in up to approximately 22% of patients) were equally distributed among
the two arms of the study. Clusterin is a complex protein, with three alternatively spliced
isoforms that have different cellular/extracellular localization (nuclear, cytoplasmic, and
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secreted/extracellular), which determines its function [39]. The nuclear form of clusterin
plays a pro-apoptotic role by displacing BAX from its complex with the DNA-binding
protein Ku70. The released BAX then inserts into the outer membrane of the mitochondria,
creating a permeability pore that facilitates cytochrome c release, leading to caspase activation, which triggers the mitochondrial cell death program [40,41]. In contrast, the cytosolic
and extracellular isoforms of Clusterin have anti-apoptotic functions by inhibiting BAX
and p53 [42,43]. Taken together with the possibility of cell lineage-dependent functional
variability, complex regulation of these three distinct isoforms of Clusterin may explain, in
part, the disappointing results of this clinical trial. A promising randomized phase II clinical
trial was established to evaluate the effect of inhibiting the anti-apoptotic proto-oncogene
Bcl-2 using the ASO oblimersen sodium in addition to docetaxel also in castration-resistant
PC [44]. The endpoint selected was a reduction of PSA > 30%, which was not achieved in
any arm of the study, indicating that oblimersen was not beneficial in this selected cohort of
111 patients. Interestingly, the expression of Bcl-2 was not analyzed, raising the possibility
of a delivery failure. Future clinical trials with oblimersen selecting tumors with known
overexpression of BCL2 or with a more granular evaluation of delivery issues may be
informative. However, major toxicity may be an obstacle to using oblimersen since significant adverse events (mainly myelosuppression) were observed in 40.7% of patients treated
with oblimersen and docetaxel in combination but only in 22.8% of those treated with
docetaxel alone. Considerable attention has been given to investigating the utilization of
the miRNA-34a (miR-34a) as a target of ncRNA “vaccines”, because it is considered a tumor
suppressor that acts in synergy with p53 and may be downregulated in several malignant
neoplasms from diverse origins, including prostate, bladder, lung, breast, gastrointestinal,
pancreas, liver, head and neck, ovary, bone and hematopoietic [45,46]. MiR-34a is transcriptionally upregulated by p53 [47] and also inhibits the epithelial–mesenchymal transition
associated with overexpression of CD44 and metastatic behavior of cancer stem cells [48,49].
Interestingly, miR-34a has been shown to directly inhibit tumor expression of the adhesion
molecule CD44, which interacts with the extracellular matrix promoting migration and
invasion of tumor cells, which is characteristic of metastatic behavior [50]. Therefore, a
phase I clinical trial using MRX34 (a liposomal mimic of microRNA-34a) was established
for advanced solid tumors as a multicenter study (NCT01829971). Unfortunately, this study
was closed prematurely due to serious adverse effects including four deaths in a cohort of
85 patients. However, the study provided additional proof of concept for using ncRNA
therapeutics, since the targeted genes were appropriately modulated, and satisfactory cytoplasmic delivery of MRX34 was demonstrated in the treated patient’s tumors by detecting
increased miR-34a expression using chromogenic in situ hybridizations [51]. MRX34 was
administered intravenously along with oral dexamethasone, and the study concluded by
emphasizing the necessity to better understand the biology of immune stimulation induced
by double-stranded RNA pharmacomimetics (such as MRX34) before implementation of
new clinical trials in humans. Surprisingly, pre-clinical animal trials did not predict the
observed toxicity, which also included immune hepatitis, myelosuppression, fever/chills,
and dyspnea.
3. Circumventing Obstacles to Efficacious Noncoding RNA Therapeutics
The immense therapeutic potential of ncRNA “vaccines” remains still unrealized,
partly due to toxicity and delivery issues, which could be tackled with evolving innovation
in the field [6]. As alluded in the preceding sections, the immunogenicity of foreign RNA
accounts for most toxic effects of ncRNA therapeutics, which activate TLR signaling and
myeloid differentiation factor 88 (MYD88), ultimately terminating in excessive release of
cytokines (IL-6, IL-8, IL-12, and TNF) and IFN type I [52]. Several approaches have been
introduced to increase the tolerability of ncRNA. As double-stranded RNA is less potent at
activating the immune system [53], all ncRNA therapeutics currently in use employ singlestranded RNA. In addition, chemical modification of the known immunogenic sequences
in ncRNA (for example GU-rich sequences such as 50 -UGUGU-30 or 50 -GUCCUUCAA-30 )
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has been engineered using various strategies, including 20 -ribose modifications of uridine
or guanosine nucleosides that can abrogate TLR stimulation [54]. Similarly, preservation of the two nucleotide-long 30 -overhangs (the natural product generated during the
biogenesis of miRNA by the enzyme Dicer) present in endogenous miRNAs has been
shown to decrease immune activation and was engineered in 50 -triphosphate-modified
siRNAs [55,56]. Despite these and several other advances in RNA chemical engineering, the
clinical trials using modified agents have been disappointing due to unacceptable toxicity
related to immune stimulation. For example, flu-like symptoms were still seen with a
modified siRNA (PRO-040201) to downregulate Apolipoprotein B in a clinical trial to treat
hypercholesterolemia (NCT00927459).
An alternative method to decrease the unwanted immunogenicity of ncRNA “vaccines”
is exemplified by third-generation modifications, such as phosphoramidate morpholino
oligomers (PMOs or simply morpholinos) that should not activate TLR signaling [57].
PMOs are small (usually 25 nucleotides long) synthetic nucleic acid molecules that bind to
native single-stranded RNAs or DNAs by standard base pairing. However, since the bases
of morpholinos are bound to methylene morpholine rings linked by phosphorodiamidate
(instead of phosphates present in natural nucleic acids), PMOs are not charged at physiologic pH, and the morpholino–RNA complexes are not degraded. Therefore, stimulation
of TLRs by RNA degradation products should not occur, and the morpholinos could be
used for the selective knockdown of genes by a mechanism analogous to siRNAs and
ASOs. For example, eteplirsen is an FDA-approved translation-blocking morpholino ASO
used in Duchenne muscular dystrophy (DMD) to induce skipping of the mutated exon in
dystrophin, which allows the translation of an almost full-length functional form of the
protein encoded by the DMD gene. Eteplirsen binds to exon 51 of dystrophin pre-mRNA,
preventing incorporation of the pathogenic missense mutation into mature mRNA, circumventing pre-mature termination of the mutated DMD gene [58]. Eteplirsen has been well
tolerated in clinical trials [59], which indicates that the chemical modification of ncRNA
agents may solve their toxic side effects [60].
Several additional strategies are being explored to overcome excessive immunogenic
effects of ncRNA agents, including screening for possible TLR activation before deployment, and using “tiny” antisense RNA, metronomic miRNA therapy, and combinatorial
RNA therapeutics, as has been thoroughly reviewed recently [6]. Interestingly, none of
these newer techniques have been attempted in PC yet, underscoring exciting future opportunities for clinical trials. At present, it remains unclear whether ncRNA “vaccines”
have been effective by directly modulating neoplastic gene expression, or indirectly by
triggering anti-tumoral immune responses. What has become clear is that achieving optimal regulation of the immunogenicity induced by ncRNA therapeutics would require a
multidisciplinary effort to further capitalize on this promising technology.
Another prominent obstacle for optimal efficacy of ncRNA products is controlling
their specific delivery.
The most common cause of termination of ncRNA “vaccine” clinical trials has been
the lack of efficacy, which may be multifactorial including stability and delivery issues.
Efforts to improve the delivery of ncRNA therapeutics must consider both the delivery of
these agents into the targeted organ, as well as access to the cytoplasm of the appropriate
cell type [61]. Various strategies are being perfected to optimize proper transport systems,
including vectors (liposomes, polymeric nanoparticles, and viruses) and conjugate delivery
methods, which have been recently reviewed elsewhere and are beyond the scope of this
article [62]. The natural instability of RNAs due to the presence of a 20 -OH group susceptible
to base-catalyzed hydrolysis and the prevalence of ribonucleases (RNAses) prompted the
development of chemical modifications of RNA therapeutics to promote stability. Firstand second-generation alterations enhanced resistance to RNAses and interactions with
proteins to deter degradation [63].
Third-generation antisense oligonucleotides (for example, locked nucleic acid, peptide
nucleic acid, and morpholino phosphoramidates) utilized modifications of the furanose
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ring and the phosphodiester bonds to improve resistance to RNAses but also to target
affinity and pharmacokinetic profiles [64], as described in preceding paragraphs.
Interestingly, local delivery schemes using lipid nanoparticle-like systems have shown
success in PC cell lines [65] and in diverse animal models [66,67], resulting in FDA approval. For example, patisiran, a siRNA-therapy used to treat amyloidosis by silencing
transthyretin [68] and the previously described liposomal mimic of miR-34a, MRX34 [51].
Novel conjugates of ncRNA with various molecules (polymers and antibodies) to improve delivery also represent promising arsenals now in early clinical trials or preclinical development.
However, none of these delivery systems has produced efficacious results in PC to date.
4. Conclusions
In conclusion, we reviewed exciting and growing applications of ncRNA therapeutics, focusing on clinical trials and future prospects for PC. The results of the trials in PC
have been so far contradictory and plagued with issues related to toxicity and suboptimal delivery. However, substantial scientific advances reaffirm the potential of ncRNA
therapeutics for the treatment of a multitude of diseases, including PC. The fact that one
ncRNA molecule controls numerous different genes in an amplifying effect reinforces the
therapeutic value of these agents.
Third-generation chemical modification of ncRNA “vaccines” has achieved a level
of sophistication that ensures acceptable tolerability and pharmacokinetic profiles. New
delivery systems, including conjugates with nanopolymers and/or specific antibodies,
highlight the promise of precise targeting. To date, most of the clinical trials have used antimiRNA ASO (antagomiRs) and siRNA, which leaves the field wide open for development
and experimentation with other ncRNA therapeutics in the future. Ample opportunities
to explore ncRNA species exist that have not been used in the clinic, such as miRNA
sponges (linear or circular artificial RNA molecules able to simultaneously inhibit more
than one species of miRNA) [69,70] or miRNA-masking ASOs (able to block the access
of native miRNA to the target mRNA by annealing to the latter in a sequence-specific
manner) [71]. Furthermore, some types of lncRNAs, such as circular RNAs or natural
antisense transcripts, may represent innovative therapeutic opportunities, which have only
recently gained attention for clinical trials [6]. The realization of the potential of ncRNA
therapeutics will require a multidisciplinary approach combining scientific advances in the
fields of molecular biology, immunology, chemistry (nanotechnology), and pharmacology,
coupled with translational research in various clinical disciplines including oncology. The
ideal ncRNA product should act specifically on one or various genetic pathways in the appropriate tissue type without eliciting intolerable toxicity related to an exaggerated immune
response. Encouraging creative solutions are emerging in ncRNA therapeutics, which allow
cautious optimism and certainly will foster additional multidisciplinary research.
In summary, the field of ncRNA therapeutics is reaching maturity and offers tremendous
hope to deliver a revolutionary change in the treatment of carcinoma and many other maladies.
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